- The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studiesMatthew J Sheetz
Eli Lilly and Company, Indianapolis, IN 46285, USA
Invest Ophthalmol Vis Sci 54:1750-7. 2013..To assess the effect of ruboxistaurin (RBX) on vision loss through a prospectively defined combined analysis of two phase 3 trials (MBDL and MBCU)...
- Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)Matthew J Sheetz
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
Retina 31:1053-9. 2011..034). This study evaluates the primary end point of SMVL in a 2-year open-label extension (OLE) of the PKC-DRS2, which began a median of 466 days (range, 263-1,296 days) after the conclusion of PKC-DRS2...